Nanoform Finland Plc – Manager’s Transactions – Albert Hæggström
Prenumeration
Beskrivning
| Land | Finland |
|---|---|
| Lista | First North Finland |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Nanoform Finland Plc | Company Release | April 02, 2026 at 09:30:00 EEST
Helsinki, Finland – Manager’s transaction related to Nanoform Finland Plc’s Member of the Board and CFO Albert Hæggström’s purchase of Nanoform Finland Plc shares:
Nanoform Finland Oyj - Managers' Transactions Nanoform Finland Oyj - Managers' Transactions
____________________________________________
Person subject to the notification requirement
Name: Albert Haeggström
Position: Chief Financial Officer
Issuer: Nanoform Finland Oyj
LEI: 743700JJO2NU8LBS1592
Notification type: INITIAL NOTIFICATION
Reference number: 150160/5/4
____________________________________________
Transaction date: 2026-04-01
Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)
Instrument type: SHARE
ISIN: FI4000330972
Nature of transaction: ACQUISITION
Transaction details
(1): Volume: 2448 Unit price: 0.457 EUR
(2): Volume: 34316 Unit price: 0.457 EUR
(3): Volume: 962 Unit price: 0.457 EUR
(4): Volume: 319 Unit price: 0.4565 EUR
(5): Volume: 1955 Unit price: 0.4565 EUR
(6): Volume: 10000 Unit price: 0.457 EUR
Aggregated transactions (6):
Volume: 50000 Volume weighted average price: 0.45698 EUR
For further information, please contact:
Henri von Haartman
Director of Investor Relations
hvh@nanoform.com
+46 7686 650 11
About Nanoform
Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its nanoforming technologies and formulation services, from pre-clinical to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: DNB Carnegie Investment Bank AB, +46 8 588 685 70, certifiedadviser@dnbcarnegie.se. For more information, please visit www.nanoform.com.